COMMUNIQUÉS West-GlobeNewswire

Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.
06/11/2018
Amsterdam, the Netherlands - 6 November 2018 The Cell Factory in collaboration with the University of Padova, Italy has completed pre-clinical in-vivo tests of the CF-MEV-132 drug candidate for the treatment of [...]
William Demant Holding A/S: Interim Management Statement covering the period year-to-date
06/11/2018
Company announcement no 2018-11 6 November 2018 Interim Management Statement covering the period year-to-date Strong organic growth in wholesale of hearing aids exceeding market growth rate in value Ongoing roll-out of [...]
PCI Biotech: Invitation to third quarter 2018 presentation
06/11/2018
Oslo, Norway, 06 November 2018 - PCI Biotech invites to a presentation of the company's third quarter 2018 report on Tuesday 13 November 2018 at Oslo Cancer Cluster Innovation Park. Time: Tuesday November 13, 08:30am – [...]
Rule 2.9 Announcement
06/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 November 2018 [...]
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
06/11/2018
Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway Progressed DPI and pMDI programs; formulations for clinical [...]
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
06/11/2018
FDA grants priority review for Dupixent ® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis Paris and Tarrytown, NY - November 6, 2018 - The U.S. Food and Drug [...]
La FDA accorde un examen prioritaire au Dupixent® (dupilumab) dans le traitement potentiel de la dermatite atopique modéré à sévère non contrôlée de l'adolescent
06/11/2018
La FDA accorde un examen prioritaire au Dupixent ® (dupilumab) dans le traitement potentiel de la dermatite atopique modéré à sévère non contrôlée de l'adolescent Paris et Tarrytown (New York) - Le 6 novembre 2018 - La [...]
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018
06/11/2018
Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage [...]
OpGen Announces Date of Third Quarter 2018 Financial Results Conference Call
05/11/2018
GAITHERSBURG, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that the Company will report financial results for the three and nine months ended September 30, 2018 after the close of [...]
Kane Biotech Appoints Dr. Gordon Guay as Chief Scientific Officer
05/11/2018
WINNIPEG, Manitoba, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced the appointment of Gordon Guay, Ph.D., a member of Kane’s [...]
Syneos Health to Present at the Jefferies 2018 London Healthcare Conference
05/11/2018
RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract [...]
The Ensign Group to Present at the 2018 Stephens Fall Investment Conference on Tuesday, November 6, 2018
05/11/2018
MISSION VIEJO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]
ReWalk Robotics to Report Third Quarter 2018 Financial Results on November 8, 2018
05/11/2018
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its third quarter 2018 [...]
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
05/11/2018
ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
INSYS Therapeutics Reports Third Quarter 2018 Results
05/11/2018
Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: [...]
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
05/11/2018
DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets
05/11/2018
Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and [...]
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05/11/2018
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- [...]
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
05/11/2018
WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and [...]

Pages